← Leaderboards
Joe W. Gray
University Of California San Francisco
$35,260,197
Attributed
$47,938,665
Total exposure
34
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.2M · FY2005–22$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$127,674,894 · 39
By mechanism
U54$67,617,297 · 18
P50$35,006,234 · 8
U2C$10,685,345 · 3
U01$6,233,577 · 2
U24$5,372,086 · 1
R44$1,717,328 · 1
Top collaborators
- Laura Madeline Heiser31 shared
- James Korkola31 shared
- Rosalie C Sears6 shared
- Claire J Tomlin6 shared
- Andrea Hope Bild5 shared
- Emek Demir5 shared
- William Evan Johnson5 shared
- Franziska Michor5 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Eun-Sil Shelley Hwang$9,292,755
- Patricia Clement Babbitt$15,142,070
- Paul R Ortiz De Montellano$16,022,859
- Thea D Tlsty$18,398,021
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsResponseBaseMalignant NeoplasmsSignal TransductionCellsMolecularTumorImageTissuesCell LineCommunitiesMeasurementProgramsMalignant Breast NeoplasmSamplingCollaborationsPharmaceutical PreparationsTechnologyGenomicsOutreachResourcesData AnalysesEvaluation
Grant awards (198)
Molecular, Cellular, and Tissue Characterization Unit$752,398
U2C · FY2022 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$307,954
U2C · FY2022 · CA · contact PI
Molecular, Cellular, and Tissue Characterization Unit$746,441
U2C · FY2021 · CA · contact PI
Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance$466,050
U54 · FY2021 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$301,997
U2C · FY2021 · CA · contact PI
Administrative Core$227,588
U54 · FY2021 · CA · contact PI
Imaging Management and Analysis Core$204,078
U54 · FY2021 · CA · contact PI
Measuring, Modeling and Controlling Heterogeneity$2,053,370
U54 · FY2020 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,757,743
U2C · FY2020 · CA
Molecular, Cellular, and Tissue Characterization Unit$733,794
U2C · FY2020 · CA · contact PI
Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance$461,333
U54 · FY2020 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$307,136
U2C · FY2020 · CA · contact PI
Administrative Core$226,782
U54 · FY2020 · CA · contact PI
Imaging Management and Analysis Core$202,163
U54 · FY2020 · CA · contact PI
Measuring, Modeling and Controlling Heterogeneity$2,164,435
U54 · FY2019 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,757,745
U2C · FY2019 · CA · contact PI
Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks$1,714,600
U54 · FY2019 · HG · contact PI
Data Analysis$773,612
U54 · FY2019 · HG
Molecular, Cellular, and Tissue Characterization Unit$749,044
U2C · FY2019 · CA · contact PI
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors$645,619
U01 · FY2019 · CA
Data Generation$627,937
U54 · FY2019 · HG
Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance$543,061
U54 · FY2019 · CA · contact PI
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$513,354
R44 · FY2019 · CA
Administrative Core$347,061
U54 · FY2019 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$326,981
U2C · FY2019 · CA · contact PI
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$233,858
R44 · FY2019 · CA
Imaging Management and Analysis Core$202,115
U54 · FY2019 · CA · contact PI
Administration$168,792
U54 · FY2019 · HG · contact PI
Outreach$144,259
U54 · FY2019 · HG
Measuring, Modeling and Controlling Heterogeneity$83,652
U54 · FY2019 · CA · contact PI
Administrative Core$13,943
U54 · FY2019 · CA · contact PI
Imaging Management and Analysis Core$13,943
U54 · FY2019 · CA · contact PI
Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance$13,941
U54 · FY2019 · CA · contact PI
Measuring, Modeling and Controlling Heterogeneity$2,191,539
U54 · FY2018 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$1,811,747
U2C · FY2018 · CA · contact PI
Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks$1,714,600
U54 · FY2018 · HG · contact PI
Molecular, Cellular, and Tissue Characterization Unit$819,068
U2C · FY2018 · CA · contact PI
Data Analysis$770,294
U54 · FY2018 · HG
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$745,151
R44 · FY2018 · CA
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors$671,607
U01 · FY2018 · CA
Data Generation$623,571
U54 · FY2018 · HG
Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance$519,083
U54 · FY2018 · CA · contact PI
Omic and Multidimensional Spatial Atlas of Metastatic Breast and Prostate Cancers$313,297
U2C · FY2018 · CA · contact PI
Administrative Core$281,333
U54 · FY2018 · CA · contact PI
Imaging Management and Analysis Core$259,913
U54 · FY2018 · CA · contact PI
Administration$174,454
U54 · FY2018 · HG · contact PI
Outreach$146,281
U54 · FY2018 · HG
Measuring, Modeling and Controlling Heterogeneity$66,990
U54 · FY2018 · CA · contact PI
Administrative Core$66,990
U54 · FY2018 · CA · contact PI
Measuring, Modeling and Controlling Heterogeneity$1,876,979
U54 · FY2017 · CA · contact PI
Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks$1,714,600
U54 · FY2017 · HG · contact PI
Data Analysis$776,554
U54 · FY2017 · HG
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors$666,735
U01 · FY2017 · CA
Data Generation$630,314
U54 · FY2017 · HG
Understanding the Impact of Microscale and Nanoscale Heterogeneity and Resistance$474,833
U54 · FY2017 · CA · contact PI
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$224,965
R44 · FY2017 · CA
Administrative Core$224,862
U54 · FY2017 · CA · contact PI
Imaging Management and Analysis Core$215,663
U54 · FY2017 · CA · contact PI
Administration$163,400
U54 · FY2017 · HG · contact PI
Outreach$144,332
U54 · FY2017 · HG
Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks$1,714,600
U54 · FY2016 · HG · contact PI
Data Analysis$776,519
U54 · FY2016 · HG
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors$672,917
U01 · FY2016 · CA
Data Generation$630,269
U54 · FY2016 · HG
Integrative signaling models to decipher complex cancer phenotypes$514,480
U01 · FY2016 · CA
Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks$175,000
U54 · FY2016 · HG · contact PI
Administration$163,458
U54 · FY2016 · HG · contact PI
Outreach$144,354
U54 · FY2016 · HG
Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks$1,714,600
U54 · FY2015 · HG · contact PI
Data Analysis$771,622
U54 · FY2015 · HG
Intratumor heterogeneity underlying treatment resistance in HER2+ breast tumors$682,376
U01 · FY2015 · CA
Integrative signaling models to decipher complex cancer phenotypes$651,183
U01 · FY2015 · CA
Data Generation$621,039
U54 · FY2015 · HG
Administration$179,018
U54 · FY2015 · HG · contact PI
Outreach$142,921
U54 · FY2015 · HG
Model-based predictions of responses RTK Pathway therapies$2,444,254
U54 · FY2014 · CA · contact PI
Extrinsic Perturbations of Cell Physiology and Associated Regulatory Networks$1,714,600
U54 · FY2014 · HG · contact PI
Data Analysis$896,441
U54 · FY2014 · HG
Integrative signaling models to decipher complex cancer phenotypes$551,268
U01 · FY2014 · CA
Modeling Response to HER2 target therapies$500,424
U54 · FY2014 · CA · contact PI
Data Generation$403,759
U54 · FY2014 · HG
Administration$222,903
U54 · FY2014 · HG · contact PI
Outreach$191,497
U54 · FY2014 · HG
Developmental Project$109,980
U54 · FY2014 · CA · contact PI
Administrative Core$74,969
U54 · FY2014 · CA · contact PI
Model-based predictions of responses RTK Pathway therapies$2,209,405
U54 · FY2013 · CA · contact PI
Integrative signaling models to decipher complex cancer phenotypes$553,275
U01 · FY2013 · CA
Modeling Response to HER2 target therapies$462,960
U54 · FY2013 · CA · contact PI
Developmental Project$97,692
U54 · FY2013 · CA · contact PI
Administrative Core$71,492
U54 · FY2013 · CA · contact PI
Model-based predictions of responses RTK Pathway therapies$2,370,950
U54 · FY2012 · CA · contact PI
Integrative signaling models to decipher complex cancer phenotypes$624,117
U01 · FY2012 · CA
Modeling Response to HER2 target therapies$504,022
U54 · FY2012 · CA · contact PI
Administrative Core$326,920
P50 · FY2012 · CA · contact PI
Risk Stratification for Subsequent Tumors in Women with DCIS$289,533
P50 · FY2012 · CA · contact PI
Genomic Approaches to Breast Cancer Subset Identification and Treatment$221,689
P50 · FY2012 · CA · contact PI
Outreach and Dissemination$164,449
U54 · FY2012 · CA · contact PI
Developmental Research Program$149,933
P50 · FY2012 · CA · contact PI
Career Development Program$149,932
P50 · FY2012 · CA · contact PI
Education & Training$133,065
U54 · FY2012 · CA · contact PI
Developmental Project$104,559
U54 · FY2012 · CA · contact PI
Administrative Core$78,695
U54 · FY2012 · CA · contact PI
Model-based predictions of responses RTK Pathway therapies$2,427,800
U54 · FY2011 · CA · contact PI
Modeling Response to HER2 target therapies$502,262
U54 · FY2011 · CA · contact PI
Administrative Core$263,774
P50 · FY2011 · CA · contact PI
Risk Stratification for Subsequent Tumors in Women with DCIS$235,119
P50 · FY2011 · CA · contact PI
Genomic Approaches to Breast Cancer Subset Identification and Treatment$179,468
P50 · FY2011 · CA · contact PI
Outreach and Dissemination$131,715
U54 · FY2011 · CA · contact PI
Developmental Research Program$120,688
P50 · FY2011 · CA · contact PI
Career Development Program$120,688
P50 · FY2011 · CA · contact PI
Developmental Project$115,221
U54 · FY2011 · CA · contact PI
Education & Training$107,382
U54 · FY2011 · CA · contact PI
BREAST ONCOLOGY PROGRAM$69,689
P30 · FY2011 · CA · contact PI
Administrative Core$68,173
U54 · FY2011 · CA · contact PI
Model-based predictions of responses RTK Pathway therapies$2,620,912
U54 · FY2010 · CA · contact PI
SPORE in Breast Cancer$2,300,000
P50 · FY2010 · CA · contact PI
Modeling Response to HER2 target therapies$549,709
U54 · FY2010 · CA · contact PI
Administrative Core$319,981
P50 · FY2010 · CA · contact PI
Risk Stratification for Subsequent Tumors in Women with DCIS$284,029
P50 · FY2010 · CA · contact PI
Genomic Approaches to Breast Cancer Subset Identification and Treatment$217,999
P50 · FY2010 · CA · contact PI
Developmental Research Program$145,296
P50 · FY2010 · CA · contact PI
Career Development Program$145,296
P50 · FY2010 · CA · contact PI
Outreach and Dissemination$135,660
U54 · FY2010 · CA · contact PI
Developmental Project$122,530
U54 · FY2010 · CA · contact PI
Education & Training$111,454
U54 · FY2010 · CA · contact PI
Administrative Core$74,468
U54 · FY2010 · CA · contact PI
BREAST ONCOLOGY PROGRAM$70,557
P30 · FY2010 · CA · contact PI
SPORE in Breast Cancer$2,180,158
P50 · FY2009 · CA · contact PI
Systems-Based Predictions of Responses to Cancer Therapy$1,317,537
U54 · FY2009 · CA · contact PI
Systems-Based Predictions of Responses to Cancer Therapy$756,483
U54 · FY2009 · CA · contact PI
Genome Based Marker and Therapy Development in Ovarian Cancer$326,685
P50 · FY2009 · CA · contact PI
Administrative Core$304,393
P50 · FY2009 · CA · contact PI
The Berkeley Cancer Genome Center$278,332
U24 · FY2009 · CA · contact PI
Risk Stratification for Subsequent Tumors in Women with DCIS$268,602
P50 · FY2009 · CA · contact PI
Genomic Approaches to Breast Cancer Subset Identification and Treatment$207,657
P50 · FY2009 · CA · contact PI
Career Development Program$137,147
P50 · FY2009 · CA · contact PI
Developmental Research Program$137,147
P50 · FY2009 · CA · contact PI
Outreach and Dissemination$133,000
U54 · FY2009 · CA · contact PI
Education & Training$110,132
U54 · FY2009 · CA · contact PI
BREAST ONCOLOGY PROGRAM$71,725
P30 · FY2009 · CA · contact PI
Systems-Based Predictions of Responses to Cancer Therapy$2,635,074
U54 · FY2008 · CA · contact PI
The Berkeley Cancer Genome Center$1,663,466
U24 · FY2008 · CA · contact PI
SPORE in Breast Cancer$1,162,500
P50 · FY2008 · CA · contact PI
SPORE in Breast Cancer$1,137,500
P50 · FY2008 · CA · contact PI
CORE--MOLECULAR AND CELLULAR PROFILING$483,858
U54 · FY2008 · CA · contact PI
Genome Based Marker and Therapy Development in Ovarian Cancer$227,260
P50 · FY2008 · CA · contact PI
Administrative Core$213,310
P50 · FY2008 · CA · contact PI
Risk Stratification for Subsequent Tumors in Women with DCIS$189,868
P50 · FY2008 · CA · contact PI
Genomic Approaches to Breast Cancer Subset Identification and Treatment$145,553
P50 · FY2008 · CA · contact PI
Developmental Research Program$95,989
P50 · FY2008 · CA · contact PI
Career Development Program$95,989
P50 · FY2008 · CA · contact PI
BREAST ONCOLOGY PROGRAM$74,361
P30 · FY2008 · CA · contact PI
Systems-Based Predictions of Responses to Cancer Therapy$2,856,441
U54 · FY2007 · CA · contact PI
SPORE in Breast Cancer$2,359,341
P50 · FY2007 · CA · contact PI
The Berkeley Cancer Genome Center$1,695,288
U24 · FY2007 · CA · contact PI
CORE--MOLECULAR AND CELLULAR PROFILING$522,777
U54 · FY2007 · CA · contact PI
SPORE in Breast Cancer$270,000
P50 · FY2007 · CA · contact PI
BREAST ONCOLOGY PROGRAM$64,895
P30 · FY2007 · CA · contact PI
Systems-Based Predictions of Responses to Cancer Therapy$2,635,056
U54 · FY2006 · CA · contact PI
SPORE in Breast Cancer$2,426,332
P50 · FY2006 · CA · contact PI
The Berkeley Cancer Genome Center$1,735,000
U24 · FY2006 · CA · contact PI
CORE--MOLECULAR AND CELLULAR PROFILING$286,641
U54 · FY2006 · CA · contact PI
SPORE in Breast Cancer$275,000
P50 · FY2006 · CA · contact PI
Systems-Based Predictions of Responses to Cancer Therapy$63,659
U54 · FY2006 · CA · contact PI
Systems-Based Predictions of Responses to Cancer Therapy$10,893
U54 · FY2006 · CA · contact PI
SPORE in Breast Cancer$2,814,351
P50 · FY2005 · CA
Systems-Based Predictions of Responses to Cancer Therapy$2,716,509
U54 · FY2005 · CA
CORE--MOLECULAR AND CELLULAR PROFILING$278,292
U54 · FY2005 · CA
SPORE in Breast Cancer$2,873,052
P50 · FY2004 · CA
Systems-Based Predictions of Responses to Cancer Therapy$1,992,262
U54 · FY2004 · CA
SPORE in Breast Cancer$527,536
P50 · FY2004 · CA
CORE--MOLECULAR AND CELLULAR PROFILING$270,186
U54 · FY2004 · CA
ADMINISTRATION AND EDUCATION$102,394
U54 · FY2004 · CA
Project 4$1
U54 · FY2004 · CA
SPORE in Breast Cancer$2,483,895
P50 · FY2003 · CA
BAY AREA BREAST CANCER TRANSLATIONAL RESEARCH PROGRAM$554,233
P50 · FY2003 · CA
SPORE in Breast Cancer$372,833
P50 · FY2003 · CA
BAY AREA BREAST CANCER TRANSLATIONAL RESEARCH PROGRAM$994,561
P50 · FY2002 · CA
GENOME EVOLUTION AND GENE DISCOVERY IN OVARIAN CANCER$230,600
P01 · FY2002 · CA
DNA SEQUENCE COPY NUMBER ABNORMALITIES IN HUMAN BREAST CANCER$206,819
P50 · FY2002 · CA
DNA SEQUENCE COPY NUMBER ABNORMALITIES IN HUMAN BREAST CANCER$206,819
P50 · FY2002 · CA
BAY AREA BREAST CANCER TRANSLATIONAL RESEARCH PROGRAM$99,167
P50 · FY2002 · CA
Core--Cell analysis laboratory$0
P30 · FY2002 · CA
BAY AREA BREAST CANCER TRANSLATIONAL RESEARCH PROGRAM$2,646,270
P50 · FY2001 · CA
BAY AREA BREAST CANCER TRANSLATIONAL RESEARCH PROGRAM$402,935
P50 · FY2001 · CA
DNA SEQUENCE COPY NUMBER ABNORMALITIES IN HUMAN BREAST CANCER$206,819
P50 · FY2001 · CA
DNA SEQUENCE COPY NUMBER ABNORMALITIES IN HUMAN BREAST CANCER$206,819
P50 · FY2001 · CA
Cancer genetics program$0
P30 · FY2001 · CA
Cancer genetics program$0
P30 · FY2001 · CA
Breast oncology program$0
P30 · FY2001 · CA
Breast oncology program$0
P30 · FY2001 · CA
GENOME EVOLUTION AND GENE DISCOVERY IN OVARIAN CANCER$0
P01 · FY2001 · CA
BAY AREA BREAST CANCER TRANSLATIONAL RESEARCH PROGRAM$2,572,530
P50 · FY2000 · CA
CORE--MOLECULAR CYTOMETRY$230,600
P01 · FY2000 · CA
ROLE OF ALLELIC IMBALANCE IN OVARIAN CANCER PROGRESSION$230,600
P01 · FY2000 · CA
DNA SEQUENCE COPY NUMBER ABNORMALITIES IN HUMAN BREAST CANCER$206,819
P50 · FY2000 · CA
Cancer genetics program$0
P30 · FY2000 · CA
Breast oncology program$0
P30 · FY2000 · CA